BOULDER, Colo., July 27, 2015 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2015 and hold a conference call to discuss those results on Monday, August 3, 2015. Ron Squarer, Chief Executive Officer will lead the call.
http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO
Date: Monday, August 3, 2015
Time: 9:00 a.m. Eastern Time
Toll-Free: (844) 464-3927
Toll: (765) 507-2598
Pass Code: 68380312
Webcast, including Replay and Conference Call Slides:
http://edge.media-server.com/m/p/999aon7i/lan/en
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six registration studies are currently advancing. These programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (AstraZeneca). For more information on Array, please go to www.arraybiopharma.com.
CONTACT: Tricia Haugeto Array BioPharma Inc. (303) 386-1193 thaugeto@arraybiopharma.com
Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-fourth-quarter-and-full-year-of-fiscal-2015-on-august-3-2015-300119132.html
SOURCE Array BioPharma Inc.